NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

PTN

Palatin Technologies Inc

May 07 • 04:00PM ET

0.0941

Dollar change 0.0000
Percentage change 0.00	%

Healthcare • Biotechnology • USA • AMEX

Peers: ACHV ATOS XBIO CTXR LBPH LPTX SCYX AKTX DBVT CNTX

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.54	Insider Own	2.63%	Shs Outstand	26.01M	Perf Week	-52.95%
Market Cap	2.45M	Forward P/E	-	EPS next Y	-	Insider Trans	17.11%	Shs Float	23.53M	Perf Month	-78.76%
Income	-	PEG	-	EPS next Q	-0.17	Inst Own	14.22%	Short Float	33.98%	Perf Quarter	-89.13%
Sales	0.35M	P/S	6.99	EPS this Y	50.99%	Inst Trans	-	Short Ratio	2.95	Perf Half Y	-92.16%
Book/sh	-0.27	P/B	-	EPS next Y	-	ROA	-	Short Interest	8.00M	Perf Year	-95.54%
Cash/sh	-	P/C	-	EPS next 5Y	-	ROE	-	52W Range	0.09 - 2.48	Perf YTD	-91.52%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-96.21%	Beta	0.72
Dividend TTM	-	Quick Ratio	-	Sales past 5Y	-	Gross Margin	-	52W Low	8.66%	ATR (14)	0.05
Dividend Ex-Date	-	Current Ratio	-	EPS Y/Y TTM	40.41%	Oper. Margin	-	RSI (14)	20.54	Volatility	15.73% 20.42%
Employees	30	Debt/Eq	-	Sales Y/Y TTM	-95.07%	Profit Margin	-	Recom	-	Target Price	7.00
Option/Short	Yes / No	LT Debt/Eq	-	EPS Q/Q	-	Payout	-	Rel Volume	0.00	Prev Close	0.09
Sales Surprise	-	EPS Surprise	71.43%	Sales Q/Q	-	Earnings	Feb 13 BMO	Avg Volume	2.71M	Price	0.09
SMA20	-57.60%	SMA50	-82.18%	SMA200	-90.60%	Trades		Volume	0	Change	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-05-15	Reiterated	Canaccord Genuity	Buy	$4 → $6
Jan-12-15	Reiterated	ROTH Capital	Buy	$6 → $4
May-23-12	Initiated	Noble Financial	Buy
Jan-23-07	Initiated	Next Generation	Buy	$5

May-15-25 03:16AM	Palatin Technologies Inc (PTNT) Q3 2025 Earnings Call Highlights: Strategic Advances Amid ... (GuruFocus.com)
02:49AM	Q3 2025 Palatin Technologies Inc Earnings Call (Thomson Reuters StreetEvents)
May-14-25 07:30AM	Palatin Reports Fiscal Year 2025 Third Quarter Results and Business Update (PR Newswire)
May-09-25 07:30AM	Palatin Presents Promising Preclinical Data on Melanocortin Agonists for Retinopathy at ARVO 2025 (PR Newswire)
May-08-25 10:19PM	Palatin Technologies Announces Closing of Reduced Public Offering (PR Newswire)
04:39PM	Loading…
04:39PM	Palatin Presents Breakthrough Symptom Resolution Data from Phase 3 PL9643 MELODY-1 Clinical Trial in Dry Eye Disease at ARVO 2025 (PR Newswire)
May-07-25 08:26PM	Palatin Technologies Announces Transition to OTC Pink Following NYSE American Delisting Notice (PR Newswire) -44.65%
08:56AM	Palatin expects $11.5M financing to cure NYSE American delisting notice (Seeking Alpha)
08:15AM	Palatin Expects $11.5 Million Financing to Cure NYSE American Delisting Notice (PR Newswire)
08:00AM	Palatin Technologies Announces Pricing of up to $23 Million Public Offering (PR Newswire)
May-05-25 07:30AM	Palatin Presents Promising Preclinical Data for Melanocortin Agonist PL9588 at ARVO 2025, Highlighting a Dual-Action Glaucoma Therapy (PR Newswire) -17.49%
Apr-29-25 05:39PM	These Charts Show How Every S&P 500 Stock Has Performed in Trumps First 100 Days (Barrons.com)
07:30AM	Palatin Announces Breakthrough Symptom Resolution in Updated Analyses from Phase 3 PL9643 MELODY-1 Clinical Trial in Dry Eye Disease (PR Newswire)
Apr-17-25 07:30AM	Palatin Reports Positive Appetite Suppression Results From Phase 2 Obesity Study of MC4R Agonist Bremelanotide and Tirzepatide (PR Newswire) -10.57%
Apr-14-25 07:00AM	Palatin Appeals NYSE American Notice of Delisting (PR Newswire) +15.39%
04:01PM	Loading…
Apr-10-25 04:01PM	Palatin Technologies, Inc. Announces Receipt of NYSE American Notice of Delisting and Intention to Appeal (PR Newswire) -60.93%
07:30AM	Palatin to Present Positive Phase 2b Data for Melanocortin Agonist in Diabetic Kidney Disease at the National Kidney Foundation Spring Meeting (PR Newswire)
Mar-31-25 07:30AM	Palatin Announces MC4R Agonist Bremelanotide Co-Administered with GLP-1/GIP Tirzepatide Meets Primary Endpoint in Phase 2 Obesity Study (PR Newswire) -11.96%
Mar-28-25 01:11PM	Palatins UC therapy prompts clinical remission in a third of patients (Clinical Trials Arena) -5.41%
07:30AM	Palatin Announces Positive Topline Results from Phase 2 Ulcerative Colitis (UC) Study of Oral Melanocortin-1 Receptor Agonist PL8177 (PR Newswire)
Mar-25-25 07:30AM	Palatin's Oral MC4R Agonist PL7737 Receives FDA Orphan Drug Designation for Obesity Due to Leptin Receptor Deficiency (PR Newswire)
Mar-13-25 09:55AM	Here's Why Palatin Technologies (PTN) Is a Great 'Buy the Bottom' Stock Now (Zacks)
Feb-14-25 03:20AM	Q2 2025 Palatin Technologies Inc Earnings Call (Thomson Reuters StreetEvents) -5.66%
02:18AM	Palatin Technologies Inc (PTN) Q2 2025 Earnings Call Highlights: Strategic Advances Amid ... (GuruFocus.com)
Feb-13-25 07:30AM	Palatin Reports Second Quarter Fiscal Year 2025 Financial Results and Provides Business Update (PR Newswire) +7.10%
Feb-10-25 04:00PM	Palatin to Report Second Quarter Fiscal Year 2025 Results; Teleconference and Webcast to be held on February 13, 2025 (PR Newswire) -8.77%
Feb-07-25 08:00AM	Palatin Announces $4.7 Million Registered Direct Offering and Concurrent Private Placement (PR Newswire) +6.06%
07:01AM	Palatin concludes Phase II trial of combination therapy for obesity (Clinical Trials Arena)
Feb-06-25 07:30AM	Palatin Completes Phase 2 Obesity Study With MC4R Bremelanotide Plus GLP-1/GIP Tirzepatide (PR Newswire) +14.32%
Jan-28-25 07:30AM	Palatin Provides Update on Anticipated 2025 Corporate Milestones (PR Newswire)
07:41AM	Loading…
Dec-20-24 07:41AM	Palatin reports positive Phase 2b results in diabetic nephropathy (TipRanks) +12.55%
Dec-19-24 07:30AM	Palatin Announces Positive Phase IIb BREAKOUT Study Results in Patients with Type 2 Diabetic Nephropathy (PR Newswire) +14.67%
Dec-16-24 07:30AM	Palatin Announces Exercise of Warrants for Approximately $3.4 Million Gross Proceeds (PR Newswire) -5.03%
Nov-25-24 07:30AM	Palatin Announces Completion of Patient Enrollment in Phase 2 Study of Orally Administered Melanocortin Agonist PL8177 in Ulcerative Colitis (PR Newswire) +14.58%
Nov-15-24 05:24AM	Q1 2025 Palatin Technologies Inc Earnings Call (Thomson Reuters StreetEvents) -12.69%
02:15AM	Palatin Technologies Inc (PTN) Q1 2025 Earnings Call Highlights: Strategic Shifts Amid Revenue ... (GuruFocus.com)
Nov-14-24 07:30AM	Palatin Reports First Quarter Fiscal Year 2025 Operating/Financial Results (PR Newswire) -10.08%
Nov-08-24 09:57AM	Palatin to Report First Quarter Fiscal Year 2025 Results; Teleconference and Webcast to be held on November 14, 2024 (PR Newswire) +12.07%
Nov-04-24 07:30AM	Palatin Presents Data on Novel Melanocortin 4 Receptor Selective Oral Small Molecule PL7737 Obesity Program at ObesityWeek 2024 (PR Newswire)
Oct-31-24 07:30AM	Palatin Completes Enrollment in Phase 2 Clinical Study of Bremelanotide (MC4R Agonist) Co-Administered with Tirzepatide (GLP-1/GIP) for the Treatment of Obesity (PR Newswire)
Oct-24-24 07:30AM	Inflammatory Disease Healing Data via Palatin's Novel Melanocortin Receptor Agonists Presented at the 19th Annual Peptide Therapeutics Symposium (PR Newswire)
Oct-23-24 07:30AM	Palatin Presents Foundational Data on Novel and Highly Selective Melanocortin 4 Receptor Agonists at the 19th Annual Peptide Therapeutics Symposium (PR Newswire)
Oct-07-24 04:15PM	Palatin Receives Notice of Non-Compliance from NYSE American (PR Newswire)
Oct-02-24 06:54AM	Q4 2024 Palatin Technologies Inc Earnings Call (Thomson Reuters StreetEvents) -6.82%
03:00AM	Palatin Technologies Inc (PTN) Q4 2024 Earnings Call Transcript Highlights: Strategic Moves and ... (GuruFocus.com)
Oct-01-24 07:30AM	Palatin Reports Fourth Quarter and Fiscal Year Ended 2024 Financial Results, Provides Update on Clinical Programs, Strategic Priorities, and Anticipated Milestones (PR Newswire)
Sep-30-24 09:01AM	Palatin Technologies Inc (PTN) Q4 2024 Earnings Report Preview: What To Expect (GuruFocus.com) +6.40%
Sep-26-24 07:30AM	Palatin to Report Fourth Quarter and Fiscal Year End 2024 Results (PR Newswire)
Sep-09-24 07:30AM	Palatin Provides Update on Clinical Programs, Strategic Priorities, and Anticipated Milestones (PR Newswire)
Aug-28-24 07:30AM	FDA Confirms Acceptability of Palatin's Remaining Phase 3 Pivotal Clinical Trials for PL9643 in Dry Eye Disease (DED) (PR Newswire) +9.40%
Aug-23-24 04:52AM	Palatin Technologies doses first subject in Phase II obesity treatment trial (Clinical Trials Arena)
Aug-22-24 07:30AM	First Patient Dosed in Phase 2 Clinical Study of Palatin's Bremelanotide Co-Administered with Tirzepatide (GLP-1) for the Treatment of Obesity (PR Newswire)
Jun-21-24 08:00AM	Palatin Announces Exercise of Warrants for Approximately $6.1 Million Gross Proceeds (PR Newswire)
04:32AM	Palatin initiates Bremelanotide-PDE5i Phase II trial for ED (Clinical Trials Arena)
Jun-20-24 07:30AM	Palatin Announces the Initiation of a Phase 2 Clinical Study of Bremelanotide Co-Administered with a PDE5i for the Treatment of Erectile Dysfunction (ED) (PR Newswire) -9.18%
Jun-13-24 06:52AM	Palatin Technologies commences Phase II study of obesity treatment (Clinical Trials Arena)
Jun-12-24 07:30AM	Palatin Initiates Phase 2 Clinical Study of Bremelanotide for the Treatment of Obesity (PR Newswire) +6.49%
May-20-24 12:00PM	Palatin Technologies (PTN) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
May-16-24 03:05AM	Palatin Technologies Inc (PTN) (Q3 2024) Earnings Call Transcript Highlights: Navigating ... (GuruFocus.com)
01:46AM	Q3 2024 Palatin Technologies Inc Earnings Call (Thomson Reuters StreetEvents)
May-15-24 07:30AM	Palatin Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update (PR Newswire) -14.11%
May-09-24 07:30AM	Palatin to Report Third Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on May 15, 2024 (PR Newswire) +14.63%
May-02-24 07:30AM	Palatin Announces FDA Clearance of IND Application for the Co-Administration of Bremelanotide with Tirzepatide (GLP-1) for the Treatment of Obesity (PR Newswire) +9.63%
Apr-30-24 07:30AM	Palatin to Host Virtual KOL Event "Beyond GLPs: The Multiple Roles for Novel Melanocortin Receptor 4 Agonists in Treating Obesity and Weight Loss Maintenance" on May 8, 2024 (PR Newswire)
Apr-14-24 03:00PM	10 Micro-Cap Healthcare Stocks Insiders Are Buying (Insider Monkey)
Apr-09-24 08:59AM	Palatin (PTN) Up 15% on Results From Dry Eye Disease Study (Zacks)
Apr-08-24 12:02PM	Palatin Technologies Eyes Growing $6B Dry Eye Disease Market With Late-Stage Study Data (Benzinga) +14.77%
07:30AM	Palatin Announces Phase 3 PL9643 MELODY-1 Dry Eye Disease (DED) Clinical Data Results Presented at American Society of Cataract and Refractive Surgery (ASCRS) 2024 (PR Newswire)
Feb-28-24 07:30AM	Palatin Announces Results of PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED) (PR Newswire) -38.29%
Feb-16-24 10:00AM	Palatin Technologies, Inc. (AMEX:PTN) Q2 2024 Earnings Call Transcript (Insider Monkey)
12:55AM	Q2 2024 Palatin Technologies Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-15-24 07:30AM	Palatin Reports Second Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update (PR Newswire) -23.91%
Feb-09-24 07:30AM	Palatin to Report Second Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on February 15, 2024 (PR Newswire) +5.72%
Feb-05-24 07:30AM	Palatin Announces Database Lock for PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED) (PR Newswire) +7.67%
Feb-01-24 04:00PM	Palatin Announces Closing of $10 Million Registered Direct Offering (PR Newswire) -14.25%
Jan-30-24 08:00AM	Palatin Announces $10 Million Registered Direct Offering (PR Newswire) -10.62%
Jan-11-24 01:38PM	3 Penny Stocks to Buy to Unlock 2,500% Upside Potential (InvestorPlace)
Jan-08-24 10:33AM	Palatin Provides Corporate Update and Highlights Strategic Priorities for Calendar Year 2024 (PR Newswire) +12.73%
Jan-03-24 08:00AM	Cosette Pharmaceuticals Acquires Vyleesi (Bremelanotide Injection) from Palatin Technologies Inc. (Business Wire) -10.62%
Dec-23-23 05:00PM	Analysts Say 3 Stocks Have a Combined Upside of 3000% (InvestorPlace)
Dec-20-23 07:30AM	Palatin Completes Sale of Vyleesi® to Cosette Pharmaceuticals for up to $171 Million (PR Newswire)
Dec-18-23 04:15PM	Palatin Receives Notice of Acceptance of the Listing Standards Compliance Plan from NYSE American (PR Newswire) -8.30%
Nov-15-23 03:01PM	Palatin Technologies, Inc. (AMEX:PTN) Q1 2024 Earnings Call Transcript (Insider Monkey)
03:29AM	Q1 2024 Palatin Technologies Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-14-23 07:30AM	Palatin Reports First Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update (PR Newswire)
Nov-09-23 07:30AM	Palatin to Report First Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on November 14, 2023 (PR Newswire)
Oct-24-23 04:50PM	Palatin Announces Closing of $5 Million Registered Direct Offering (PR Newswire)
Oct-23-23 07:30AM	Palatin Announces $5 Million Registered Direct Offering (PR Newswire) -13.75%
Oct-19-23 08:45AM	Melanocortin Receptor R&D to Target Increasing Prevalence of Obesity-Related Disorders (PR Newswire) +22.54%
07:30AM	Palatin Announces Preliminary Quarter Ended September 30, 2023 Vyleesi® Product Revenue Results (PR Newswire)
Oct-18-23 07:30AM	Palatin Announces Positive Preclinical Data Showing Synergistic Weight Loss; Initiating Clinical Study of Melanocortin 4 Receptor Agonist + GLP-1 in Obese Patients (PR Newswire)
Oct-16-23 07:30AM	Palatin Presents Data at the United European Gastroenterology Week 2023 Conference On PL8177 Ulcerative Colitis Treatment (PR Newswire)
Oct-13-23 04:15PM	Palatin Receives Notice of Non-Compliance from NYSE American (PR Newswire)
Oct-03-23 08:35AM	Palatin Technologies, Inc. (AMEX:PTN) Q4 2023 Earnings Call Transcript (Insider Monkey)
Sep-29-23 01:34AM	Q4 2023 Palatin Technologies Inc Earnings Call (Thomson Reuters StreetEvents)
Sep-28-23 07:30AM	Palatin Reports Fourth Quarter and Fiscal Year Ended 2023 Financial Results and Provides Corporate Update (PR Newswire) -9.09%
Sep-22-23 04:00PM	Palatin to Report Fourth Quarter and Fiscal Year End 2023 Results; Teleconference and Webcast to be held on September 28, 2023 (PR Newswire) -5.66%
Sep-07-23 04:00PM	Palatin to Present at the H.C. Wainwright 25th Annual Global Investment Conference (PR Newswire) -7.14%
07:30AM	Palatin Completes Enrollment in Phase 3 MELODY-1 Study of PL9643 For the Treatment of Patients with Dry Eye Disease (PR Newswire)
Aug-10-23 07:30AM	Palatin Initiates Clinical Program for Bremelanotide Co-Formulated with a PDE5i for the Treatment of ED in Patients Non-Responsive to PDE5i Treatment (PR Newswire) -5.50%

Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that is in Phase 2 clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease, which is in Phase 3 clinical trial; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL8177, an oral peptide formulation for treatment of ulcerative colitis, which entered Phase 2 clinical trials. Palatin Technologies, Inc. was founded in 1986 and is based in Cranbury, New Jersey.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
DEVEER ROBERT K JR	Director	May 07 '25	Buy	0.10	100,000	10,180	138,065	May 12 09:30 PM
WILLS STEPHEN T	Executive VP and CFO/COO	Aug 01 '24	Sale	1.66	4,999	8,274	235,456	Aug 02 05:01 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PTN

Palatin Technologies Inc

Upgrade your FINVIZ experience